Do you want to know us better?
DOWNLOAD OUR PRESS KIT
OUR NEWS
SOLTI strengthens its business development plan by adding Ramón Mel to its Management Team
This appointment is part of the Group’s strategic plan for the period 2024-2027, defined after the designation of the current Executive Board with Dr. Mafalda Oliveira
21 de March de 2024
“Invertir en formación es clave para que las pacientes con cáncer de mama adquieran un mayor control sobre las decisiones que afectan a su salud”
Dr. Tomás Pascual, oncólogo médico y Director Científico de SOLTI: SOLTI ha afianzado su apuesta formativa para pacientes con cáncer de mama a través de
21 de December de 2021
TOTHER3 study demonstrates the usefulness of a new immunoconjugate, now in early breast cancer
Within the framework of the San Antonio Breast Cancer Symposium – SABCS 2021 The benefit of the antibody-drug conjugate (ADCs) patritumab deruxtecan is successfully measured for
13 de December de 2021